SCHEMBL5061920

SCHEMBL5061920

CSc1ncc2cc(-c3cc(NC(=O)Nc4cnn(C(C)(C)C)c4)c(F)cc3F)c(=O)n(C)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.46
RAF1 P04049 3/20 0.46
FGFR1 P11362 4/20 0.36
KDR P35968 3/20 0.36
PDGFRA P16234 6/20 0.36
KIT P10721 3/20 0.36
WEE1 P30291 5/20 0.34
MAP2K2 P36507 2/20 0.34
MAP2K1 Q02750 2/20 0.34
KRAS P01116 1/20 0.34
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
MAPK10 P53779 3/20 0.33
MAPK8 P45983 3/20 0.33
MAPK9 P45984 1/20 0.33
ABL1 P00519 5/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4427764 0.94 RAF1 (0.45) BRAFRAF1FGFR1KDRPDGFRA
SCHEMBL4420381 0.94 BRAF (0.54) BRAFRAF1FGFR1KDRPDGFRA
SCHEMBL5057392 0.89 BRAF (0.40) BRAFRAF1FGFR1KDRPDGFRA
SCHEMBL4563335 0.88 BRAF (0.60) BRAFRAF1FGFR1KDRPDGFRA
SCHEMBL5063013 0.84 SYK (0.45) BRAFRAF1FGFR1KDRPDGFRA
SCHEMBL5061721 0.82 BRAF (0.58) BRAFRAF1FGFR1PDGFRAKIT
SCHEMBL5066945 0.82 BRAF (0.69) BRAFRAF1FGFR1KDRPDGFRA
SCHEMBL4562874 0.81 BRAF (0.52) BRAFRAF1FGFR1KDRPDGFRA
SCHEMBL4433688 0.81 RAF1 (0.46) BRAFRAF1FGFR1KDRPDGFRA
SCHEMBL4274943 0.81 BRAF (0.48) BRAFRAF1MAPK14CSF1RFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885FGFR1 577/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885FGFR1 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.